Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Risperidone long-acting injectable - Teva

Next Previous
Drug Profile

Risperidone long-acting injectable - Teva

Alternative Names: mdc-IRM; TEV-46000; TV-46000; UZEDY

Latest Information Update: 06 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Teva Branded Pharmaceutical Products R&D
  • Developer MedinCell S.A.; Teva Branded Pharmaceutical Products R&D
  • Class Antidepressants; Antineoplastics; Antipsychotics; Behavioural disorder therapies; Fluorinated hydrocarbons; Isoxazoles; Mood stabilisers; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 5-HT2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Schizophrenia
  • Preregistration Bipolar disorders
  • Preclinical Neurological disorders

Most Recent Events

  • 25 Feb 2025 Preregistration for Bipolar disorders in USA (SC)
  • 25 Feb 2025 US FDA accepts sNDA for Risperidone for Bipolar disorders for review
  • 21 Sep 2024 Pharmacokinetics data from population pharmacokinetic (PopPK) analysis released by Teva Pharmaceutical Industries

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top